# Autologous Natural Killer T Cells Infusion for the Treatment of Cancer

> **NCT01801852** · NA · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Breast Cancer
- Glioma
- Hepatocellular Cancer
- Squamous Cell Lung Cancer
- Pancreatic Cancer
- Colon Cancer
- Prostate Cancer

## Interventions

- **BIOLOGICAL:** NKT cells

## Key facts

- **NCT ID:** NCT01801852
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-01
- **Primary completion:** 2016-05
- **Final completion:** 2017-06
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2016-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01801852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01801852, "Autologous Natural Killer T Cells Infusion for the Treatment of Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01801852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*